Objective To develop a decision-support tool to help policy-makers in subSaharan Africa assess whether intermittent preventive treatment in infants (IPTi) would be effective for local malaria control.
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Introduction
The burden of severe forms of Plasmodium falciparum malaria is concentrated in young children and a recent pooled analysis showed that this is even more pronounced for malaria leading to death than for less severe forms of the disease. 1 The targeted provision of insecticide-treated nets to pregnant women 2 showed an overall protective efficacy of 30% (95% confidence interval, CI: [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] against clinical malaria, 38% (95% CI: 13-56) against hospital admission for infection with malaria parasites, 23% (95% CI: 10-34) against all-cause hospital admission and 21% (95% CI: 8-33) against anaemia in the first year of life. 11 One trial in an area of very high drug resistance to sulphadoxine-pyrimethamine showed that such treatment had no effect, although the long-acting drug mefloquine had a protective efficacy of 38% against clinical malaria. 10 The strategy of administering IPTi using an efficacious, long-acting antimalarial drug therefore has merit. A recent World Health Organization (WHO) consultation document recommended that IPTi with sulphadoxine-pyrimethamine (IPTi-SP) be considered under certain epidemiological conditions in which the drug combination is effective.
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There has been some debate about where IPTi should be introduced because the burden of clinical malaria extends beyond infancy and, in some settings, infection is concentrated in only a few months of the year. [13] [14] [15] It is not feasible to carry out large-scale randomized controlled trials to determine the effectiveness of IPTi against severe outcomes in a wide range of different settings. Alternative methods are therefore needed to determine where IPTi is likely to be most beneficial. In this study, we attempted to solve this problem using two approaches: a secondary analysis of existing research data and a stochastic mathematical model.
As the epidemiology of malaria is complex and heterogeneous and even varies over small distances, it is difficult to develop a universal malaria control policy that is 
Methods
Age pattern analysis
A pooled analysis of available data on the age pattern of outcomes of P. falciparum malaria was undertaken and has been described elsewhere. 1 In brief, a systematic literature review was used to determine the age distribution of patients with clinical malaria, of those admitted to hospital with malaria parasites (i.e. those in whom malaria infection was confirmed after hospital admission for severe symptoms) and of those whose death was diagnosed as due to malaria by verbal autopsy. Data were collected in 21 sub-Saharan African countries from a total of 61 research sites, each of which was categorized as having a low, medium or high intensity of malaria transmission according to whether the entomological inoculation rate (EIR) was < 10, 10-100 or > 100 infective bites per person per year, respectively, as determined from temporally matched and georeferenced data, or whether the georeferenced prevalence of malaria parasites in children aged under 5 years was < 25%, 25-60% or > 60%, respectively. Each site was also categorized according to whether or not malaria transmission was markedly seasonal: the cut-off criterion was that at least 75% of clinical episodes occurred within a period of 6 months or less throughout the year, as previously described. 16 Where local data were unavailable, experts with local knowledge were consulted.
For each study, the age distribution of patients aged 0-10 years with each malaria-related outcome was calculated. Data from sites classified as being in the same intensity and seasonality categories were grouped together to form a 3 × 2 matrix. The five principle and most widely used continuous probability distributions were fitted to the age distributions for each outcome and each of the six malaria transmission categories using maximum likelihood methods. The probability Publication: Bulletin of the World Health Organization; Type: Research Article ID: BLT.09.072397 distribution that best fitted the data was taken to represent the patients' age profile and was presented graphically. 1 The percentage of cases of each malaria-related outcome in children under 10 years of age (excluding neonates among those whose death was diagnosed as due to malaria) that would be targeted by IPTi was calculated by integrating the area under the probability distribution curve for infants between 3 and 12 months of age.
This was done because this age range covers those children who would be most likely to receive IPTi-SP in practice, since, in all the trials, IPTi-SP was administered with the third dose of the diphtheria-tetanus-pertussis combined vaccine (DTP3) and with measles immunization to children approximately 3 and 9 months of age, respectively.
The range was extended to 12 months to take into account variations in the actual age at which IPTi-SP was given and because its protective effect has been reported to last 1 to 2 months after each dose.
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Stochastic model A stochastic mathematical model was developed to predict the impact of IPTi because research data on some malaria-related outcomes and epidemiological settings were incomplete: in particular, none of the IPTi-SP trials discussed above was powered to detect an effect on mortality, and EPI coverage and health-system functioning were relatively good in the trial settings, but not necessarily elsewhere. Moreover, IPTi may have consequences for the development of immunity over time. The model developed here was used to predict the likely impact of IPTi-SP in different settings up to 10 years after its introduction.
A comprehensive, individual-based, stochastic model of malaria epidemiology had been developed previously. 19 Briefly, malaria-related outcomes in a simulated population are updated in 5-day time steps in a process that takes into account variables representing new infections, parasite density (i.e. the number of parasites per microlitre of blood), acquired immunity to malaria, uncomplicated and severe episodes of malaria, direct and indirect malaria-related mortality and infectivity to mosquitoes (i.e. the likelihood that a mosquito feeding on an infected human will itself become infected). The model also took into account the action of sulphadoxine-pyrimethamine, as determined by Hastings and Watkins, 20 and the final model was validated 21 using the results of the six IPTi-SP trials.
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The model was used to explore factors that influence the effectiveness of IPTi. Africa. 22 The following assumptions were made for all settings: 4% of clinical cases 23 and 48% of severe cases 24 (i.e. cases that should be admitted to hospital) were treated effectively in each 5-day interval; the drug combination used was sulphadoxine-pyrimethamine, and the prevalence of the dhfr double and triple mutations, which are markers for sulphadoxine-pyrimethamine drug resistance, were low at 10% and 10%, respectively. Since IPTi is expected to have the greatest impact when a long-lasting effective drug is administered, 21 in line with trial findings, 
Decision-support tool
An algorithm for predicting the effect of IPTi-SP was developed using the results of the two approaches described above (Fig. 1) . Firstly, when using the tool, the country and the first administrative level (i.e. the highest subnational administrative division)
are selected from a comprehensive list of all countries in sub-Saharan Africa. The intensity and seasonality of malaria transmission are then categorized using published data, if available. In addition, the user can alter the data presented, thereby enabling the decision-support tool to incorporate alternative or additional information. Next, the IPTi-SP administration schedule is selected from the DTP2, DTP3 and measles infant immunization schedule for the country concerned. coverage.
For the scenario specified by the user, the decision-support tool provides graphical information on the predicted age distributions of patients with clinical malaria, of those admitted to hospital with malaria parasites and of those who will die due to malaria. In addition, the percentage of cases of each malaria-related outcome in children under the age of 10 years that would be targeted by the IPTi strategy is estimated. Further, the stochastic model produces estimates of the predicted number of cases of each malaria-related outcome that would be averted if IPTi-SP were implemented, while taking into account the expected treatment programme coverage and using the assumptions about health-system coverage, the effectiveness of treatment and the level of drug resistance described above.
Results
Age pattern analysis
The percentage of cases of malaria-related outcomes occurring in children aged under 10 years that would be targeted by IPTi was estimated from the age patterns of Typically, the age distribution of patients admitted to hospital with malaria parasites is skewed towards younger children and this skew becomes more pronounced as the intensity of transmission increases. Consequently, IPTi could target 9 to 29% of these cases, depending on the transmission setting. Given the pooled estimate of 38% for the protective efficacy of IPTi-SP against this outcome, 11 IPTi could prevent 3 to 11% of admissions with malaria parasites during childhood, depending on the epidemiological setting.
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Deaths diagnosed as due to malaria were heavily concentrated in very young children and, although no data were available to predict the age pattern with a low intensity of transmission, there appeared to be a shift towards younger ages as the intensity of transmission increased. Consequently, IPTi could target 17 to 41% of all childhood deaths diagnosed as due to malaria in settings with a medium-to-high intensity of transmission. To date, the protective efficacy of IPTi against death due to malaria or any other cause is unknown, so we were unable to estimate the percentage of deaths that could be averted by IPTi.
Stochastic model
The results of the stochastic model have been presented in detail elsewhere. 21 The model predicted that the number of episodes of malaria that would be averted by
IPTi would increase when IPTi coverage increased, when treatment coverage by the local health system decreased, and when drugs that were more effective or had a longer prophylactic period were introduced. 21 In addition, the number of cases averted was higher when IPTi doses were timed so that the prophylactic periods did not 
Decision-support tool
The decision-support tool provides predictions for each specified scenario in two parts. The first is a graph of the expected age pattern of clinical malaria cases, cases admitted to hospital with malaria parasites and deaths diagnosed as due to malaria for the one of the six intensity and seasonality categories derived from study data that best matches the specified scenario (Fig. 2) . In addition, the percentage of cases of each malaria-related outcome that would be targeted by IPTi is listed. The second part is a table derived by the stochastic model detailing the predicted number of cases of each outcome that could be averted in infants aged under 12 months in the specified scenario, that is, according to the specified epidemiological setting and IPTi dosing schedule and coverage and using the underlying assumptions described above (Fig.   3 ).
Discussion
The intensity of transmission is known to influence the age pattern of severe P.
falciparum malaria and there is evidence that it also affects other malaria-related outcomes. 1 In addition, there is increasing evidence that this pattern changes as the intensity of transmission declines, 13, 28 though malaria-related deaths still tend to be concentrated in the very young. 29 The changing epidemiology of malaria makes it difficult to predict the potential impact of new control strategies. Moreover, as transmission intensity declines, the heterogeneity of malaria infection is likely to increase and the need for subnational policy-making will grow. The decision-support tool described here is intended to meet that need by enabling malaria control programme managers in sub-Saharan Africa to assess the potential benefits of IPTi under different epidemiological conditions and with varying levels of treatment coverage.
The methodologies used to produce the predicted age pattern of malariarelated outcomes and the predicted number of cases averted have several limitations, which have been discussed separately elsewhere by Carneiro et al. 1 and Ross et al., The main limitation of the decision-support tool lies in determining the appropriate category for the intensity of transmission in the selected first administrative level in a specific country since the EIR varies significantly over space and time and few robust data are available for most settings. We also used the parasite prevalence in children, which has a log-linear relationship with the EIR, 34, 35 to classify the intensity of transmission. Broad categories for the intensity of transmission were used in both the analyses and the decision-support tool to avoid giving the impression that intensity could be determined precisely for a given site while still allowing some general and consistent patterns to be discerned. Given these caveats, the decision-support tool was designed to be sufficiently flexible to allow the user to incorporate local knowledge or temporal changes by including additional data on the EIR or parasite prevalence or by altering the categories allocated by the tool for the intensity and seasonality of transmission. Work is ongoing on improving the accuracy of the allocated intensities of transmission using parasite prevalence maps from the Malaria Atlas Project. 36, 37 Another limitation is that the model predictions took into account only a limited number of input variables for each setting. Variations in factors such as the level of drug resistance and health system coverage will also have an influence. Future development of the decision-support tool will enable users to alter the prevalence of drug resistance and local health system costs.
Although none of the trials on the administration of chemoprophylaxis to infants [38] [39] [40] [41] [42] and none of the IPTi trials were powered to detect an effect on mortality in infants, one chemoprophylaxis trial in the Gambia reported a statistically significant reduction in mortality in children with malaria aged 1 to 4 years old (P = 0.03). 38 Our The number of indirect deaths and, to a lesser extent, the number of severe malaria episodes predicted by the model partly rely on functions that represent the age-dependent risk of comorbid conditions. Comorbidity is assumed to weaken the host so that clinical malaria becomes severe. In the model, an indirect death was defined as a death that would not have occurred in the absence of prior malaria exposure but which was associated with a terminal illness that would not have been diagnosed as malaria by a competent physician. 32 In settings where health-care provision is good, the pattern of comorbid conditions may be quite different from that assumed in our model.
Both the percentage and number of cases that could be averted by IPTi estimated by the model will be lower than comparable estimates for similar interventions that target children over a wider age range. The strategy of seasonally administering intermittent preventive treatment in children aged under 5 years (IPTc) provides almost continuous chemoprophylaxis during the period of peak transmission and has proven highly effective against clinical malaria. [45] [46] [47] [48] However, the main concern with IPTc, and with any extension of IPTi beyond infancy, is the logistical complexity of delivering treatment in a sustainable and cost-effective manner. Studies of the efficacy of IPTc indicate that the cost would be considerably higher than for IPTi, which can take advantage of the health-care infrastructure that already exists for EPI, making it a highly cost-effective addition to existing malaria control interventions. 49 It is unclear whether IPTi and IPTc must be mutually exclusive or whether they can be complementary in areas with highly, but not exclusively, seasonal transmission.
Recently, there has been a move away from targeting specific age groups towards universal coverage for malaria interventions. 50 While our data support this trend for areas where the intensity of transmission is low, there is clearly still a role for targeting infants using interventions that can reduce the number of malariaassociated deaths. Consequently, IPTi may still form a highly cost-effective component of malaria control strategies in large swathes of Africa where access to curative services is poor at present and will remain so for years to come. Fig. 1 . Flowchart illustrating the use of a decision-support tool for predicting the effect of intermittent preventive treatment for malaria in infants in different scenarios in sub-Saharan Africa DTP3, third dose of diphtheria-tetanus-pertussis combined vaccine; EPI, Expanded Programme on Immunization; IPTi, intermittent preventive treatment in infants.
a Malaria transmission intensity is categorized as low, medium or high according to whether the entomological inoculation rate is < 10, 10-100 or > 100 infective bites per person per year, respectively.
b The selected data are described as "robust" when based on screened epidemiological data.
c The selected data are described as "indicative" when based on additional unscreened data provided by the user.
d The selected data are described as based on "user perception" if not based on epidemiological data. e Malaria transmission is categorized as seasonal when at least 75% of clinical episodes occur within a period of 6 months or less. 
